News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

credentis ag Extends Its Leadership Into the Field of Dentistry


7/22/2013 2:01:20 PM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

July 22, 2013 -- credentis ag elected at the annual general assembly Dr. Michael Peetz as a new member of the board of directors, expanding its expertise into the field of dentistry. Peetz, born in 1957, studied Pharmacy in Munich, Germany and Austin, Texas. After an extended stay to pursue his research in San Francisco, he joined the pharmaceutical company Hoechst (now Sanofi-Aventis) in the clinical research department. Between 1990 – 2008, Dr. Michael Peetz held several positions at Geistlich Biomaterials—including CEO beginning in 1998. He was responsible for developing Geistlich Biomaterials, becoming number one globally in bone and tissue regeneration in the field of dentistry. From 2008 - 2012 he was CEO of Camlog Biotechnologies in Basel, Switzerland, an international leader in implant dentistry with a worldwide distribution network.

Dr. Peetz was also co-founder and director of the Osteology Foundation, in Lucerne, Switzerland, a foundation that deals with research and education in regenerative dentistry. Since 2012, he has been President of Digital Dental Life AG, specializing in the licensing of their Web technology to the Dental Campus Association for the online training of dentists in the field of implantology. Curodont™ and Curolox™ technologies

The patented Curolox™ technology is based on peptides self-assembling into a matrix, triggering a biomimetic mineralisation and repair mechanism. The breakthrough is the basis for several innovative credentis products.

Curodont™ Repair provides dentists with a non-invasive option for natural mineralisation rather than classical repair of carious lesions. Applied to an early lesion, Curodont™ Repair forms a scaffold within the lesion to allow new hydroxyapatite crystals to form and grow. Ideally, the lesion will mineralise within several weeks. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont™ Repair shows tremendous potential in the treatment of early dental caries.

Curodont™ Protect uses the Curolox™ technology to protect the tooth surface from acid attack and to treat unpleasant tooth sensations. According to CEO, Dominik Lysek, “Curodont™ Protect has its main benefit in prophylaxis and in the treatment of dentin hypersensitivity.”

The clinical data obtained in proof-of-concept clinical studies present a milestone for credentis, showing the successful in-depth treatment of tooth decay. credentis, with its regenerative product line, launches a trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions, avoiding frequent recalls by dentists and hygienists.

About credentis ag

credentis ag is headquartered in the Technopark, Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Fund, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of Leeds.

Dominik Lysek, CEO; Michael Hug, CTO; and Tobias Feger, CBO, have a strong track record in medical technology, marketing and networking in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES